Stay updated on Satralizumab in Thyroid Eye Disease Clinical Trial
Sign up to get notified when there's something new on the Satralizumab in Thyroid Eye Disease Clinical Trial page.

Latest updates to the Satralizumab in Thyroid Eye Disease Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe revision label updated from v3.3.1 to v3.3.2; no visible changes to study content.SummaryDifference0.0%

- Check21 days agoChange DetectedPublications section wording updated to indicate PubMed publications are automatically filled from PubMed and may not be about the study; the revision tag was updated from v3.2.0 to v3.3.1.SummaryDifference0.1%

- Check29 days agoChange DetectedA new publication reference about Satralizumab in Thyroid Eye Disease was added to Publications, and a government funding lapse notice along with an older PubMed citation were removed.SummaryDifference0.3%

- Check36 days agoChange DetectedAdded study site names Centro Oftalmologico Dr. Charles S.A., Medizinische Universitat Wien, and Universitatsklinikum Munster. Removed the previous diacritic-heavy spellings Centro Oftalmológico Dr. Charles S.A., Medizinische Universität Wien, Universitätsklinikum Münster from the Locations section.SummaryDifference0.3%

- Check64 days agoChange DetectedAdded new Publications section with a PubMed-listed 2025 study design for satralizumab in thyroid eye disease; no deletions present. This expands the core content with up-to-date research references.SummaryDifference3%

- Check71 days agoChange DetectedMajor update to core page content: adds a government funding notice and current operating status details, plus a version bump to v3.2.0; removes the previous v3.1.0 reference.SummaryDifference3%

Stay in the know with updates to Satralizumab in Thyroid Eye Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Satralizumab in Thyroid Eye Disease Clinical Trial page.